These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12231070)

  • 41. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
    Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
    Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
    Wang LG; Mencher SK; McCarron JP; Ferrari AC
    Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
    Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
    Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
    Miyamoto H; Yeh S; Lardy H; Messing E; Chang C
    Proc Natl Acad Sci U S A; 1998 Sep; 95(19):11083-8. PubMed ID: 9736693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.
    Gioeli D; Black BE; Gordon V; Spencer A; Kesler CT; Eblen ST; Paschal BM; Weber MJ
    Mol Endocrinol; 2006 Mar; 20(3):503-15. PubMed ID: 16282370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
    Zhang Y; Wang XW; Jelovac D; Nakanishi T; Yu MH; Akinmade D; Goloubeva O; Ross DD; Brodie A; Hamburger AW
    Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9890-5. PubMed ID: 15994225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.
    Haapala K; Hyytinen ER; Roiha M; Laurila M; Rantala I; Helin HJ; Koivisto PA
    Lab Invest; 2001 Dec; 81(12):1647-51. PubMed ID: 11742035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
    Patki M; Chari V; Sivakumaran S; Gonit M; Trumbly R; Ratnam M
    J Biol Chem; 2013 Apr; 288(16):11047-65. PubMed ID: 23426362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
    Steinkamp MP; O'Mahony OA; Brogley M; Rehman H; Lapensee EW; Dhanasekaran S; Hofer MD; Kuefer R; Chinnaiyan A; Rubin MA; Pienta KJ; Robins DM
    Cancer Res; 2009 May; 69(10):4434-42. PubMed ID: 19366804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.